Jeremy Springhorn

Bio:

Jeremy has been Chief Executive Officer of Nido Biosciences since April 2021 and has more than 30 years of experience leading scientific, business development and corporate strategy. Prior to joining Nido, Jeremy held various senior positions including Chief Business Officer of Syros Pharmaceuticals, and Partner of Corporate Development at Flagship Pioneering, where he worked with companies in various strategic and corporate development capacities, creating the next generation of startups. Prior to Flagship, Jeremy spent more than 20 years at Alexion. He was one of the original scientists at Alexion as well as one of the original inventors of Soliris®. He moved from research to business development, ultimately becoming the Vice President of Corporate Development. In that role, Jeremy led the acquisitions of Enobia Pharma, Taligen Therapeutics and Orphatec, as well as the partnership with Moderna Therapeutics. Jeremy also served in a key strategic role as Alexion transitioned from a development-stage to a global commercial-stage company. He serves on the boards of directors of uniQure, N.V (NASDAQ:QURE) and NMD Pharma (Private) as well as the Board of Advisors for Mythic Therapeutics.